Targeting the RB tumor suppressor in breast cancer treatment
Official title: RB tumor suppressor as a therapeutic target in ER-positive breast cancer
Funded at Roswell Park Cancer Institute Corp · NIH-10798148 · Data updated 2026-11-12
This study is looking at how changes in a specific cancer-fighting pathway affect the treatment of estrogen receptor-positive metastatic breast cancer, with the goal of finding better ways to overcome resistance to common therapies and improve outcomes for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Roswell Park Cancer Institute Corp NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project start | March 1, 2020 |
| Project end | February 28, 2026 |
| Funding year | 2024 |
| Award (this year) | $408,055 |
| NIH project number | 5R01CA247362-05 |
| Project ID | NIH-10798148 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with estrogen receptor-positive metastatic breast cancer, especially those experiencing treatment resistance.
✕Less likely to help
Patients with non-ER+ breast cancer or those who are not metastatic may not benefit from this research.
What this research studies
This research investigates the role of the RB tumor suppressor pathway in the treatment of estrogen receptor-positive (ER+) metastatic breast cancer. It aims to understand how disruptions in this pathway contribute to resistance against common therapies, such as endocrine treatments and CDK4/6 inhibitors. By analyzing the mechanisms of resistance and exploring new therapeutic strategies, the research seeks to improve treatment outcomes for patients with this type of breast cancer. The approach includes drug screening and the use of organoid models to identify effective treatment regimens.
Why it matters
Potential benefit: If successful, this research could lead to more effective therapies for patients with ER+ breast cancer, particularly those who have developed resistance to current treatments.
How similar studies have gone: Previous research has shown promising results in targeting cell cycle pathways in cancer treatment, indicating that this approach may be effective.
Where this research is happening
-
Roswell Park Cancer Institute Corp
Buffalo, United States Active
Researchers
- Principal investigator: Knudsen, Erik — Roswell Park Cancer Institute Corp
- Study coordinator: Knudsen, Erik
Related research
Other NIH-funded projects on the same topics.
-
Targeting the RB tumor suppressor to improve treatment for ER-positive breast cancer
This study is looking at how a specific pathway in our cells, called the RB tumor suppressor pathway, influences the treatment of estrogen receptor-positive breast cancer, with the goal of finding better ways to help patients respond to common therapies and overcome challenges when tumors stop responding to treatment.
-
Improving Breast Cancer Guideline Adherence in Nigeria
Aimed at helping doctors in Nigeria follow international guideline-based breast cancer care to improve outcomes for women with breast cancer.
-
Genomic study to understand how genetics and epigenetics shape triple-negative breast cancer in African ancestry
This study looks at how inherited genes and gene activity affect triple-negative breast cancer in people of African ancestry to better understand why outcomes can be worse.
-
Translational breast cancer research to improve treatment options
A comprehensive program at Baylor College of Medicine is focusing on breast cancer; researchers will advance targeted therapies and biomarkers to help patients with aggressive or hard-to-treat forms.
-
Cancer Pain Management for Asian American Breast Cancer Survivors with Depressive Symptoms
A technology-based program helps Asian American breast cancer survivors with depressive symptoms manage chronic pain more effectively from home using a web app and mobile tools.
-
Co-Targeting IL-6 and CDK4/6 to Prevent TNBC in Women Veterans
A study aims to block two cancer-promoting pathways (IL-6 and CDK4/6) to prevent or reduce progression of triple-negative breast cancer in women veterans.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.